Autopsy report · NCT04270929

Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma

“Insufficient accrual rate”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Roger Williams Medical Center

Sponsor type

University, hospital or other

Conditions

Pancreatic Adenocarcinoma

Interventions

FOLFIRI; FOLFIRINOX; TriSalus Infusion System

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
  “Insufficient rate of accrual” (98% match in meaning)
• Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer
  “Accrual rate was too low” (89% match in meaning)
• A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI
  “Poor accrual rate” (86% match in meaning)
• Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
  “Low accrual rate” (85% match in meaning)
• PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer
  “Insufficient accrual” (85% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.